science wire

Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc.

Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche today announced the submiss

HRH The Duke of Sussex met scientists and clinical experts from the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust during a visit to the world's first specialist military and civilian wound research centre.

New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara * (68.4% versus 55.9%, respectively)   Results from CLARITY study presented in 2018 showed Cosentyx was significantly more effective than Stelara * in delivering clear and almost clear skin at 12 and 16 weeks.

University of Birmingham Professor Grant Stewart has received £246,993 from Great Ormond Street Hospital Children's Charity and children's medical research charity Sparks to fund research into the advancement of treatment of skeletal disorders.

Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta? (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment

The University of Oxford and Harrington Discovery Institute at University Hospitals have announced a new affiliation to advance therapies for rare diseases.

UC Berkeley synthetic biologists have engineered brewer's yeast to produce marijuana's main ingredients-mind-altering THC and non-psychoactive CBD-as well as novel cannabinoids not found in the plant itself.

Roche to acquire Spark Therapeutics for US$ 114.50 per share Spark Therapeutics is a leader in discovering, developing and delivering gene therapies with one commercial asset and four programm

Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns Polatuzumab vedotin has shown significant potential to improve outcomes

Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and

Researchers are investigating the effectiveness of non-opioid pain relief for people with acute whiplash.

Around 7,000 strokes each year are being prevented thanks to GPs more than doubling the number of patients at high risk being prescribed with drugs to prevent blood clotting, University of Birmingham researchers have found. Researchers from the University of Birmingham's Institute for Applied Health Research analysed general practice records of five million patients from 2000 to 2016 to find out how many people have a diagnosis of atrial fibrillation and how many are receiving treatment to prevent strokes.

Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO   Fascioliasis, commonly known as liver fluke infes

Alto Pharmacy uses software and an innovative operations model to improve access to medication. Getting medication to a patient requires coordination between the doctor who writes the prescription, the insurance company that provides coverage, and the pharmacy that ultimately hands over the drug.

A University of Glasgow spinout which is bringing to market a fast, affordable and efficient new way to diagnose diseases has received a major funding boost.

GPs and pharmacists struggle to find the time to involve patients in medication reviews, despite National Institute for Health and Care Excellence (NICE) guidance advising them to do so, according to a study by researchers at the University of Bristol's Centre for Academic Primary Care.

A research facility that aims to improve the quality of life, treatment and care for children with complex diseases formally opened this month.

New Haven, CT -   Dr. Tom Lynch, former Director of Yale Cancer Center and current Chief Scientific Officer at Bristol-Myers Squibb, returned to campus Wednesday to deliver a talk on 'Cancer Drug Discovery: Role of the University/Hospital, Biotech and Pharma to Improve Patient Outcomes." The talk was the first in a series presented by the Blavatnik Fund for Innovation at Yale, administered by the Office of Cooperative Research.

Editor's note: This piece was adapted from a story that originally appeared in the  University of Chicago Magazine.

When a person takes a puff on a cigarette, nicotine floods into the brain, latching onto receptors on the surface of neurons and producing feelings of happiness.

Roche's application is being reviewed under the US FDA's Real-Time Oncology Review and Assessment Aid pilot programmes Kadcyla was granted Breakthrough Therapy Designation for this application Ro

A new treatment for enlarged prostates can reduce side effects and has the potential to improve the lives of thousands of men, says an Imperial expert The treatment, which uses steam, has been shown to shrink prostates by 36 per cent and has fewer side effects than current methods.

The University of Nottingham has won new funding for five centres that will train the brightest postgraduate researchers to tackle pressing global challenges, and keep the UK at the cutting edge of scientific research.

The Centre for Rapid Online Analysis of Reactions (ROAR) is the first national centre for the study of reactions, focusing on data-centric chemistry. ROAR is the flagship Research Facility for the Dial-a-Molecule Grand Challenge , which aims to make the synthesis of any desired molecule 'as easy as dialling a number'.

Recommendation based on the Phase III IMpower150 study which showed that Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) helped people

First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis in a prospective intra-patient comparison First new class of medicine in nearly 20 years for people wit

Imperial College London will establish a new centre for myeloma research at Hammersmith Hospital, thanks to a £10 million donation.

A patient arrives at the hospital with a raging fever and chills radiating throughout his entire body.

A better understanding of risks and causes of harm for out of hours palliative care is urgently needed to ensure patient safety, finds a study carried out by researchers at Cardiff University.

The Alzheimer's Prevention Initiative (API) study of crenezumab in familial Alzheimer's disease continues Roche remains committed to ongoing clinical studies in Alzheimer's disease, including GRADUAT

Two hallmarks of the integrated stress response of cells are the inhibition of translation and the formation of stress granules (SGs) and processing bodies (PBs). However, it is not well understood how both processes are coupled. In a study published in Molecular Cell, researchers from the Chao group applied single-molecule RNA imaging to study the interactions of mRNAs with SGs and PBs, and found out that the generally accepted assumptions about the function of granules need to be revised.

The College of MVLS's Wellcome Centre for Molecular Parasitology has had a name change to better reflect its current world-changing research expertise.

The new NHS 10-year plan launched earlier this month [7 January] states all patients in England will have access to a "digital first primary care offer", such as GP online consultations, by 2022/23.

To foster community engagement, the university will create a vision to transform the White Plaza area into a vibrant town center.

Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Tecentriq (atezolizumab) in combination with Abra

Scientists at Cardiff University are helping to bring personalised treatments for Parkinson's disease closer to the clinic, thanks to a major investment of over £50,000 from American charity, The Summit for Stem Cell Foundation.